Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
143.00    0.50 (0.35%)
Bid:
142.00
Ask:
144.00
Spread: 2.00 (1.408%)
Market Cap: £121.02m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Holding(s) in Company

3 Jul 2020 10:43

RNS Number : 9949R
Diaceutics PLC
03 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Diaceutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Gresham House Asset Management Limited

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

Baronsmead Venture Trust plc - 2.21%

Baronsmead Second Venture Trust plc - 2.49%

LF Gresham House UK Micro Cap Fund - 6.54%

City and country of registered office (if applicable)

London, UK

5. Date on which the threshold was crossed or reachedvi:

30/06/2020

6. Date on which issuer notified (DD/MM/YYYY):

02/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.23%

N/A

11.23%

84,068,923

Position of previous notification (if

applicable)

10.65%

10.65%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJQTGV64

9,443,000

11.23%

SUBTOTAL 8. A

9,443,000

11.23%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

Gresham House Asset Management Limited

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

Place of completion

Gresham House Asset Management Limited, London

Date of completion

02/07/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLKXLBBBDLZBBL
Date   Source Headline
17th Dec 202410:46 amRNSHolding(s) in Company
17th Dec 20247:00 amRNSDiaceutics Wins New $5.1m Contract
10th Dec 20243:14 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSAwarded UK Research Institute Grant Funding of £1m
3rd Dec 20242:24 pmRNSTotal Voting Rights
28th Nov 20247:00 amRNSExpansion of US Commercial Activities
5th Nov 20247:00 amRNSCapital Markets Webinar
4th Nov 20247:00 amRNSHolding(s) in Company
30th Oct 20242:58 pmRNSPDMR Shareholding/Share Incentive Plan
29th Oct 202410:27 amRNSBoard Change Update
25th Oct 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
24th Oct 202412:53 pmRNSCancellation of Share Premium Account
15th Oct 20247:00 amRNS-RDiaceutics Announces Key Leadership Appointment
7th Oct 20241:19 pmRNSHolding(s) in Company
7th Oct 20247:00 amRNSBlock Listing Return
2nd Oct 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Oct 20247:00 amRNSBoard Changes
17th Sep 20247:00 amRNSH1 2024 Results - Continued Performance & Growth
9th Sep 20247:00 amRNSNotice of Results & Presentations
2nd Sep 20247:00 amRNSAppointment of Nominated Adviser and Broker
30th Aug 20243:45 pmRNSPDMR Shareholding/Share Incentive Plan
27th Aug 20247:00 amRNSDiaceutics Launches Enhanced Rare-Disease Offering
19th Aug 20247:00 amRNSEnterprise Partnership and Launch of PMx
5th Aug 20247:00 amRNSPresenting at Canaccord Genuity Growth Conference
29th Jul 20246:09 pmRNSPDMR Shareholding/SIP and TVR
29th Jul 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
23rd Jul 20247:05 amRNSBoard Changes
23rd Jul 20247:00 amRNSRevenue growth of 24% in H1 with 55% now recurring
11th Jul 20247:00 amRNSSenior Management Appointments
1st Jul 20247:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
24th Jun 20241:15 pmRNSResult of AGM
6th Jun 20247:00 amRNSDiaceutics - Capital Markets Event
29th May 20248:00 amRNSNotice of AGM and Posting of Annual Report
28th May 20247:00 amRNSData to be Presented at 2024 ASCO Annual Meeting
24th May 20243:01 pmRNSPDMR Shareholding/SIP and Total Voting Rights
23rd May 20247:00 amRNSDirector / PDMR Shareholding
21st May 20247:00 amRNSRevenue growth of 22% & order book growth of 57%
16th May 20247:00 amRNSTwo New Enterprise-Wide Engagements
14th May 20247:00 amRNSDiaceutics - Capital Markets Event
1st May 20247:00 amRNSNotice of Results & Presentations
30th Apr 20247:00 amRNSPDMR Shareholding/SIP and TVR
9th Apr 20247:00 amRNSAppointment of Amie Mc Neice as VP of Marketing
5th Apr 20241:40 pmRNSBlock Listing Return
3rd Apr 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
2nd Apr 20247:00 amRNSDirector/PDMR/PCA Shareholding & TR1
21st Mar 20247:00 amRNSSignificant upgrade to Diaceutics' DXRX platform
19th Mar 20247:00 amRNSDiaceutics forms landmark industry Forum
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSPDMR Shareholding / SIP and TVR
27th Feb 20247:00 amRNSExpanded lab network and data capabilities

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.